Journal of Chromatography B, 809 (2004) 351–356
New method for the chiral evaluation of mirtazapine
in human plasma by liquid chromatography
Fernando José Malagueño de Santana, Evandro José Cesarino, Pierina Sueli Bonato∗
Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Av. Café SN, CEP 14040-903, Ribeirão Preto, SP, Brazil
Received 6 May 2004; received in revised form 15 July 2004; accepted 16 July 2004
Available online 3 August 2004
Abstract
A simple, rapid and sensitive high-performance liquid chromatography (HPLC) method was developed for the enantioselective analysis
of the new antidepressant drug mirtazapine in human plasma. The procedure involved liquid–liquid extraction using toluene, followed by
liquid chromatography coupled to UV detection at 292 nm. The chromatographic separation of the (+)-(S)- and (−)-(R)-enantiomers of
mirtazapine was achieved on a Chiralpak AD column (250 mm × 4.6 mm, 10 m particle size) protected with a CN guard column, using
hexane–ethanol (98:2, v/v) plus 0.1% diethylamine as the isocratic mobile phase, at a flow rate of 1.2 ml/min. The total analysis time was
less than 12 min per sample. The recoveries of (+)-(S)- and (−)-(R)-mirtazapine were in the 88–111% range with a linear response over the
6.25–625 ng/ml concentration range for both enantiomers. The quantification limit (LOQ) was 5 ng/ml. Within-day and between-day assay
precision and accuracy were studied at three concentration levels (10, 50 and 250 ng/ml). For both mirtazapine enantiomers, the coefficients
of variation (CV) and deviation from the theoretical value were lower than 15% at all concentration levels. The method proved to be suitable
for pharmacokinetic studies.
© 2004 Elsevier B.V. All rights reserved.
Keywords: Enantiomer separation; Mirtazapine; Antidepressant; Chiral stationary phase
1. Introduction
Mirtazapine is a chiral drug (1,2,3,4,10,14b-hexahydro-2methylpyrazino-[2,1-a]-pyrido[2,3-c][2]benzazepine), commercialized as a 50:50 mixture of (+)-(S)- and
(−)-(R)-enantiomers, and used as an antidepressant in
the treatment of moderately and severely depressed hospitalized and out-patients [1]. Mirtazapine acts as an antagonist
of ␣2 -adrenergic auto and heteroreceptors, resulting in
increased release of norepinephrine and serotonin. It is also
an antagonist of postsynaptic serotonin type 2 (5-HT2 ) and
type 3 (5-HT3 ) [1,2].
After oral administration, mirtazapine is rapidly and completely absorbed, and then extensively biotransformed in the
liver [3]. The biotransformation of mirtazapine includes 8∗ Corresponding author. Tel.: +55 16 6024261; fax: +55 16 6332960.
E-mail address: psbonato@fcfrp.usp.br (P.S. Bonato).
1570-0232/$ – see front matter © 2004 Elsevier B.V. All rights reserved.
doi:10.1016/j.jchromb.2004.07.012
hydroxylation, N(2)-demethylation, N(2)-oxidation, as well
as direct conjugation of the drug with glucuronic acid and
conjugation of its metabolites with glucuronic or sulphuric
acid [3,4].
The pharmacokinetics and pharmacodynamics of mirtazapine appear to be enantioselective, as shown by the
differences in the kinetic parameters and effects of its
enantiomers [3,5]. The enantiomers of mirtazapine show
different receptor binding affinity. The ␣2 -autoreceptor and
5-HT2 blocking effects of mirtazapine are present primarily
in the (+)-(S)-enantiomer of mirtazapine, whereas the
␣2 -heteroreceptor and 5-HT3 type receptor antagonistic activities reside predominantly in the (−)-(R)-enantiomer [6].
After single oral dose administration, the (−)-(R)-enantiomer
appears in plasma at up to three times the concentration and
has a longer plasma half-life than the other enantiomer [3,5].
A study of the metabolism of mirtazapine enantiomers by
human cytochrome P450 enzymes demonstrated that (+)-
352
F.J.M. de Santana et al. / J. Chromatogr. B 809 (2004) 351–356
(S)-mirtazapine was extensively metabolised by CYP2D6
[7].
The separation and quantification of the enantiomers may
be important to allow therapeutic drug monitoring and the
determination of the clinical response and of the pharmacokinetic properties of the drug. Several non-chiral analytical methods have been described for the determination of
racemic mirtazapine (rac-mirtazapine) in human plasma and
serum, including high-performance liquid chromatography
(HPLC) with fluorescence [8–11] and ultraviolet detection
[12] and gas chromatography (GC) [13,14]. Some methods
to quantify rac-mirtazapine in pharmaceutical forms were
described using capillary electrophoresis (CE) [15,16] and
UV–vis spectrophotometry [17].
To our knowledge, only one chromatographic chiral
method has been described in the literature for the determination of mirtazapine enantiomers in biological fluid by
high-performance liquid chromatography with UV detection
[18].
This study describes a novel, rapid and sensitive analytical chiral method for the quantification of mirtazapine enantiomers in plasma samples using high-performance liquid
chromatography under normal-phase conditions. Validation
parameters of the method were calculated in terms of recovery, linearity, precision, quantification limit and accuracy.
2. Experimental
2.1. Chemicals and reagents
Rac-mirtazapine (laboratory code Org 3770, purity
≥98%) and rac-demethylmirtazapine were kindly supplied
by Analytical Control Labs., N.V. Organon (Oss, The
Netherlands). Hexane, methanol, ethanol and toluene were
purchased from Merck (Darmstadt, Germany) and were of
chromatography grade. Diethylamine was supplied by Fluka
(Buchs, Switzerland) and sodium hydroxide was obtained
from Nuclear (São Paulo, Brazil), both of analytical grade.
2.2. Apparatus and chromatographic conditions
Analyses were conducted using a Shimadzu (Kyoto,
Japan) liquid chromatograph, with an LC-AT VP solvent
pump unit and an SPD-10A UV–vis detector operating at
292 nm. Injections were performed manually through a 50 l
loop with a Rheodyne model 7125 injector (Rheodyne, Cotati, USA). Data were collected using a Chromatopak CR6A
integrator (Shimadzu, Kyoto, Japan). To establish the elution
order, a Jasco CD-1595 circular dichroism detector (Jasco,
Tokyo, Japan) was used. The resolution of the mirtazapine
enantiomers was evaluated at 23 (±2) ◦ C on several chiral
columns, i.e. Chiralpak AD (250 mm × 4.6 mm, 10 m
particle size), Chiralpak AD-RH (150 mm × 4.6 mm, 5 m
particle size), Chiralcel OG (250 mm × 4.6 mm, 10 m
particle size), Chiralcel OJ (250 mm × 4.6 mm, 10 m par-
ticle size) (all purchased from Chiral Technologies, Exton,
PA, USA), Ultron ES-OVM (150 mm × 4.6 mm, Rockland
Technologies, Newport, DE, USA) and a Chiral AGP
column (150 mm × 4.0 mm, 5 m particle size, ChromTech
AB, Hägersten, Sweden). A CN column (4 mm × 4 mm,
5 m particle size, Merck, Darmstadt, Germany) was used
as guard column. The best resolution was achieved on the
Chiralpak AD column using hexane–ethanol (98:2, v/v) plus
0.1% diethylamine as the mobile phase, at a flow-rate of
1.2 ml/min.
2.3. Calibration and internal quality control solutions
Human plasma samples from healthy volunteers were supplied by The Blood Center of the University Hospital, Faculty
of Medicine of Ribeirão Preto (University of São Paulo, São
Paulo, Brazil). Individual plasma samples were evaluated for
endogenous interference before use.
Stock standard and working solutions were prepared in
methanol in the concentration range of 6.25–625 g/ml. They
were stored frozen at −20 ◦ C and protected from direct light,
remaining stable for at least 3 month.
Measurements were performed on 1 ml drug-free fresh
frozen plasma spiked with 25 l of standard solutions of
(+)-(S)-mirtazapine and (−)-(R)-mirtazapine. No internal
standard was used in this method. Plasma quality controls
(QC) spiked with 10, 50 and 250 ng/ml of both enantiomers
were prepared to measure the accuracy and precision of the
method.
2.4. Sample preparation procedure
A 100 l aliquot of 10 mmol sodium hydroxide and 4 ml of
the extracting solvent toluene were added to 1 ml of unknown
plasma samples, spiked plasma samples or quality control
samples. The mixture was submitted to mechanical shaking
at 200 rpm for 30 min and centrifuged at 1800 × g for 10 min.
Appropriate volumes (3 ml) of the upper organic phases were
transferred to conical tubes and the contents were evaporated
to dryness under a gentle stream of compressed air at room
temperature. The residues were dissolved in 100 l of the
mobile phase and 50 l was injected into the chromatographic
system.
2.5. Validation of the method
The recovery of each mirtazapine enantiomer was determined at plasma concentrations of 6.25, 12.5, 62.5, 125 and
625 ng/ml (n = 3 for each concentration). Drug-free plasma
samples (1 ml) were spiked with known amounts of mirtazapine to obtain the concentrations previously specified. These
samples were submitted to the extraction procedure and their
concentrations were determined on the basis of a calibration
curve obtained by the direct injection of mirtazapine enantiomers in the mobile phase.
353
F.J.M. de Santana et al. / J. Chromatogr. B 809 (2004) 351–356
Linearity of the analytical method was evaluated by
analysing spiked plasma samples for each concentration (n =
2) over the concentration range of 6.25–625 ng/ml for each
enantiomer of mirtazapine. The results were plotted on a
graph of peak height (Y) versus plasma concentration (X)
and the best relationship was obtained by linear least-squares
regression analysis.
The sensitivity of the method was evaluated by determining the quantification limit (LOQ). The LOQ was defined as
the lowest mirtazapine enantiomers concentration that could
be determined with an accuracy and a precision below 20%
over five analytical runs with 1.0 ml of plasma and was obtained using plasma samples (n = 5) spiked with 5 ng/ml of
each mirtazapine enantiomer.
The precision and accuracy of the method were determined over 4 days. Each day, one calibration curve and 15
determinations of five quality controls in three concentrations, 10, 50 and 250 ng/ml of each mirtazapine enantiomers
were performed. The within-day (n = 5) and between-day (n =
4) results were expressed as relative standard deviations (coefficient of variation, CV) and deviation from the theoretical
value, respectively.
To assess the applicability of the validated method, mirtazapine enantiomers were determined in plasma samples
collected from a healthy volunteer after a single oral administration of 30 mg of rac-mirtazapine (Remeron® , N.V.
Organon). Venous blood was collected into heparinized tubes
at 0, 1, 2, 3, 5 and 12 h after drug administration and the tubes
were centrifuged for 10 min at 1800 × g. The plasma samples
obtained were stored at −20 ◦ C until analysis. We also analyzed a plasma sample collected at steady state (immediately
before drug administration) from a patient under depression
treatment. The volunteers gave written informed consent to
participate in the investigation, which was approved by the
Ethics Committee of the Faculty of Pharmaceutical Sciences
of Ribeirão Preto–University of São Paulo (process number
19-CEP/FCFRP).
Fig. 1. Chromatograms referring to the separation of mirtazapine enantiomers on different columns and under different chromatographic conditions (as specified in Table 1).
3. Results and discussion
3.1. Chromatographic and extraction conditions
The chiral resolution of mirtazapine enantiomers was
evaluated in several cellulose and amylose derivatives
and protein-based chiral stationary phases: Chiralcel OG,
Chiralcel OJ, Chiralpak AD, Chiralpak AD-RH, Ultron
ES-OVM and Chiral AGP column (Fig. 1). The first three
columns were evaluated under normal phase conditions
using hexane–isopropanol or hexane–ethanol as the mobile
phase. Diethylamine was added to these mobile phases in
order to reduce the interaction of the basic drug with the
silanol groups of the silica support. The other three columns
were evaluated under reversed phase conditions using
buffer–acetonitrile or buffer–methanol mixtures. Table 1
describes the optimized chromatographic conditions as well
as the retention and separation parameters.
Table 1
Optimized chromatographic conditions for the chiral separation of mirtazapine in plasma
Mobile phase
N
Rs
F
Chiralpak AD
Hexane:ethanol (98:2, v/v) + diethylamine (0.1%, v/v)
4010
1.82
1.5
Chiralcel OJ
Hexane:ethanol (98:2, v/v) + diethylamine (0.1%, v/v)
1600
0.86
Chiralcel OG
Hexane:ethanol (98:2, v/v) + diethylamine (0.1%, v/v)
2153
Chiral AGP
Ammonium acetate 10 mmol/l, pH 5.5:acetonitrile (95:5, v/v)
ULTRON-ES-OVM
Sodium phosphate 70 mmol/l, pH 4.8:acetonitrile (95:5, v/v)
CHIRALPAK AD-RH
Sodium borate 20 mmol/l, pH 9.2:acetonitrile (70:30, v/v)
α
As
3.41
1.16
1.1
1.5
1.96
1.15
1.2
1.78
1.5
1.84
1.15
1.1
762
1.23
1.0
27.06
1.20
2.0
563
1.75
1.0
4.36
1.40
1.4
416
0.9
1.0
12.23
1.15
1.5
k1
N, theoretical plates; Rs, resolution; F, flow-rate (ml/min); k1 , retention factor for the first eluted enantiomer (tm was defined as the first significant baseline
disturbance, corresponding to the retention time of a non retained solute); α, separation factor; As, asymmetry factor for the first eluted enantiomer.
354
F.J.M. de Santana et al. / J. Chromatogr. B 809 (2004) 351–356
Under the chromatographic conditions described on
Table 1, the Chiralpak AD column was chosen once it provided better resolution and efficiency as well as relatively
short retention times (Table 1 and Fig. 2). The use of a CN
guard column to protect the column evaluated did not disturb
significantly the chromatographic behavior.
Dodd et al. [18] reported the separation of mirtazapine enantiomers in the Chiralpak AD column using
hexane–ethanol–isopropanol (98:1:1, v/v) as the mobile
phase, imipramine as the internal standard and solid-phase
extraction (SPE) to prepare the samples. The detection was
carried out at 290 nm. The method described in this paper uses
hexane–ethanol (98:2, v/v) as the mobile phase plus 0.1% diethylamine. The addition of diethylamine to the mobile phase
resulted in narrower peaks than the above method, improving
the resolution. Furthermore, we used a simpler procedure to
prepare the sample (liquid–liquid extraction), which resulted
in excellent recovery of drug enantiomers with suitable precision and accuracy.
The elution order was defined by submitting racmirtazapine to circular dichroism (CD) detection using the
same chromatographic conditions as described above and
comparing the CD spectra of pure enantiomers with those
presented by Moody et al. (Fig. 3) [19].
The elution order was also evaluated by analysing the pure
enantiomers (obtained by semipreparative analysis under the
conditions established in the present paper) using the procedure described by Dodd et al. [18]. The use of a different
mobile phase did not change the elution order of mirtazapine
enantiomers.
The N-demethyl metabolite of mirtazapine is not measured by this method, but under the chromatographic condition established, the enantiomers of the metabolite elute at
retention time of 58 min (not resolved). In the analysis of
real samples the injection time should be controlled in order
to avoid the co-elution of this metabolite from a previously
injected sample. The chromatograms were free from interfering peaks e.g. no significant co-elution with endogenous
compounds was found. Representative chromatograms of a
Fig. 3. CD Chromatogram (detection at 250 nm) of a rac-mirtazapine and
CD spectra of (+)-S-mirtazapine and (−)-R-mirtazapine. Chromatographic
conditions were as specified on Fig. 2.
drug-free plasma sample, a spiked plasma sample and a patient plasma sample are illustrated in Fig. 2.
3.2. Method validation
The liquid–liquid extraction recoveries obtained were between 88 and 111%, with CV values lower than 5.5% for both
enantiomers (Table 2) and show that the method is suitable
for the analysis of both enantiomers in biological fluids.
The method proved to be linear over the concentration
range of 6.25–625 ng/ml, with typical calibration curve equations determined as Y = −582.44 + 797.91X and Y = −571.05
+ 673.24X for the (+)-(S)- and (−)-(R)-enantiomers of mirtazapine, respectively, and a determination coefficient (r2 )
≥0.991.
The excellent accuracy and precision of the assay are summarized in Table 3. The within-day assay coefficients of variation (CVs) for all compounds were lower than 3.8% and all
between-day assay CVs were below 10.3%. The within-day
and between assay accuracies for all compounds were found
to be within 1.3 and −7.2% for 10 ng/ml, 3.9 and −4.7% for
50 ng/ml and 5.5 and −4.3% for 250 ng/ml. The lowest concentration quantified by the validated method (LOQs) was
5 ng/ml (Table 3), a lower value than that reported in the literature (10 ng/ml) [18].
Table 2
Mean recovery of mirtazapine enantiomers in plasma
Fig. 2. Chromatograms referring to drug-free plasma (A), plasma spiked
with 12.5 ng/ml of (+)-(S)-mirtazapine (1) and (−)-(R)-mirtazapine enantiomers (2) (B) and plasma sample collected from a patient under mirtazapine treatment (C). The analysis was performed on a Chiralpak AD column
using hexane:ethanol (98:2, v/v) plus 0.1% diethylamine at a flow rate of
1.2 ml/min, = 292 nm.
Plasma concentration
(ng/ml, n = 3)
(+)-R-mirtazapine
6.25
12.5
62.5
125
625
111.1
97.5
94.3
88.6
99.9
3.8
5.5
3.4
5.3
2.2
107.1
97.5
95.8
90.8
92.8
4.2
4.8
3.8
5.4
3.0
96.5
9.2
96.8
7.1
Range (6.25–625)
(−)-S-mirtazapine
Recovery (%) CV (%) Recovery (%) CV (%)
n, Number of samples; CV, coefficient of variation.
355
F.J.M. de Santana et al. / J. Chromatogr. B 809 (2004) 351–356
Table 3
Precision, accuracy and limit of quantification for the analysis of mirtazapine enantiomers in plasma
Nominal standard concentration (ng/ml)
Within-day (n =
5e
10
50
250
a
c
d
e
Accuracya
(−)-(S)-
(+)-(R)-
(−)-(S)-
(+)-(R)-
(−)-(S)-
5.00
9.94
50.18
252.49
4.47
10.13
51.93
263.62
0.0
−0.6
0.4
1.0
−10.7
1.3
3.9
5.4
10.7
3.0
2.1
2.2
9.0
3.1
3.0
3.8
9.28
47.63
239.15
9.56
48.33
242.88
−7.2
−4.7
−4.3
−4.4
−3.3
−2.8
5.0
4.6
4.0
10.3
6.1
4.7
Precisionb
(+)-(R)-
5)c
Between-day (n = 4)d
10
50
250
b
Analysed concentration (ng/ml)
Expressed as deviation from the theorical values.
Expressed as coefficient of variation.
Number of samples.
Number of days.
Quantification limit.
The method developed here proved to be highly selective since the retention times for the drugs analyzed
under the same chromatographic conditions of mirtazapine
analysis were not similar to those obtained for mirtazapine
enantiomers (Table 4).
The developed and validated method was used in the
analysis of some samples collected from a patient under mirtazapine treatment and from a healthy volunteer after a single
oral administration of rac-mirtazapine. The chromatogram
in Fig. 2C obtained from the patient shows higher concentrations of (−)-(R)-mirtazapine ((−)-(R)-/(+)-(S)-mirtazapine
= 1.14), in agreement with literature data [3,5,18].
In contrast, the analysis of the samples collected from
the healthy volunteer showed a higher concentration of
the (+)-(S)-enantiomer (Fig. 4). Since (+)-(S)-mirtazapine
is preferentially cleaved via 8-hydroxylation catalysed by
the CYP2D6 isoenzyme, this result is in accordance with
the hypothesis of the subject been a poor metaboliser
[3].
Table 4
Evaluation of the interference of some drugs in the analysis of mirtazapine
enantiomers
Drug
tR
Drug
tR
Alprazolam
Atenolol
Bromazepam
Caffeine
Clobazam
Disopyramide
Phenobarbital
Fluoxetine
Flunitrazepam
Imipramine
Lidocaine
Metoprolol
ND
ND
ND
ND
ND
19.2/27.0
ND
ND
ND
17.1/19.2
17.5/19.6
ND
Mexiletine
Mirtazapine
N-demethyldiazepam
N-demethylmirtazapine
Pindolol
Procainamide
Propranolol
Salbutamol
Triazolam
Trimetropim
Verapamil
ND
9.5/11
ND
58
ND
ND
15.0/33.6
ND
ND
ND
17.5/19.6
tR : Retention time in minutes; ND, not detected by the chromatographic
method up to 60 min run time.
Fig. 4. Time-concentration profile of mirtazapine enantiomers after oral administration of the racemic drug.
4. Conclusion
A simple, rapid, sensitive and reproducible HPLC method
using a common UV detector and liquid–liquid extraction
was developed for the measurement of the two enantiomers
of mirtazapine in human plasma. The Chiralpak AD column
proved to be the most suitable column for the resolution of
mirtazapine enantiomers under the chromatographic conditions used. The validated method allows the determination of
mirtazapine in the 6.25–625 ng/ml range with a quantification
limit of 5 ng/ml for both enantiomers. The values of validation presented in this paper demonstrate that the method is
superior to the other method described in the literature for
the analysis of mirtazapine enantiomers.
Acknowledgments
The authors are grateful to Fundação de Amparo a
Pesquisa do Estado de São Paulo (FAPESP) and CNPq
356
F.J.M. de Santana et al. / J. Chromatogr. B 809 (2004) 351–356
(Conselho Nacional de Desenvolvimento Cientı́fico e Tecnológico) for financial support and for granting a research
fellowship.
References
[1] T. Puzantian, Am. J. Health-Sys. Pharma. 55 (1998) 44.
[2] J.M. Gorman, J. Clin. Psychiatry 60 (1999) 9.
[3] C.J. Timmer, J.M. Ad Sitsen, L.P. Delbressine, Clin. Pharmacokinet.
38 (2000) 461.
[4] J. Fawcett, R.L. Barkin, J. Affect. Disorders 51 (1998) 267.
[5] L.P.C. Delbressine, M.E.G. Moonen, F.M. Kaspersen, G.N. Wagenaars, P.L. Jacobs, C.J. Timmer, J.E. Paanakker, H.J.M. van Hal, G.
Voortman, Clin. Drug Invest. 15 (1998) 45.
[6] C. McGrath, G.D. Burrows, T.R. Norman, Eur. J. Pharmacol. 356
(1998) 121.
[7] S. Dodd, D.W. Boulton, G.D. Burrows, C.L. DeVane, T.R. Norman,
Hum. Psychopharmacol. Clin. Exp. 16 (2001) 541.
[8] F.A. Maris, E. Dingler, S. Niehues, J. Chromatogr. B 721 (1999)
309.
[9] P.E. Morgan, J. Tapper, E.P. Spencer, J. Chromatogr. B 798 (2003)
211.
[10] P. Ptacek, J. Klima, J. Macek, J. Chromatogr. B 794 (2003) 323.
[11] M. Shams, C. Hiemke, S. Härtter, Ther. Drug Monit. 26 (2004) 78.
[12] T. Romiguieres, F. Pehourcq, M. Matoga, B. Begaud, C. Jarry, J.
Chromatogr. B 775 (2002) 163.
[13] J.E. Paanakker, H.J.M. van Hal, J. Chromatogr. 417 (1987) 203.
[14] G. Voortman, J.E. Paanakker, Hum. Psychopharmcol. Clin. Exp. 10
(1995) 83.
[15] G.S. Wynia, G. Windhorst, P.C. Post, F.A. Maris, J. Chromatogr. A
773 (1997) 339.
[16] L. Labat, P. Dallet, E. Kummer, J.P. Dubost, J. Pharm. Biomed. Anal.
28 (2002) 365.
[17] N. Karasen, S. Altinöz, J. Pharm. Biomed. Anal. 24 (2000) 11.
[18] S. Dodd, G.D. Burrows, T.R. Norman, J. Chromatogr. B 748 (2000)
439.
[19] J.D. Moody, J.P. Freeman, P.P. Fu, C.E. Cerniglia, Drug Metab. Dispos. 30 (2002) 1274.